 The FDA has granted Fast Track designation to Applied Therapeutics Incs NASDAQ: APLT AT-007 to treat Galactosemia, a rare metabolic disease. AT-007 is the Companys central nervous system-penetrant Aldose Reductase inhibitor in development for multiple rare metabolic disorders. 